Indian Pharma inches closer to US markets
The recent spate of US FDA clearances for Indian anti-retroviral drugs opened up a host of new foreign markets to the manufacturers giving hope to the industry to eventually penetrate the US market

Ind-Swift gets DCGI approval for anti-diarrhoeal drug
Chandigarh-based Ind-Swift has received approval for its quinoline-derivative, anti-diarrhoeal plus antibacterial drug, from the Drug Controller General of India (DCGI). “The drug has successfully completed all stages of clinical trials and the company expects to launch it next month,” informs V K Mehta, Managing Director, Ind-Swift.